Research programme: viral protein translation inhibitors - Anima Biotech
Alternative Names: Viral protein translation inhibitors - Anima BiotechLatest Information Update: 03 Jan 2022
At a glance
- Originator Anima Biotech
- Class Antivirals; Small molecules
- Mechanism of Action Viral protein translation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 03 Jan 2022 Discontinued for Respiratory syncytial virus infections in USA (unspecified route) (Anima Biotech pipeline, January 2022)
- 02 Aug 2018 Anima Biotech has patent protection for translation control discovery platform (Anima Biotech website, August 2018)
- 02 Aug 2018 Early research in Respiratory syncytial virus infections in USA (unspecified route) (Anima Biotech pipeline, August 2018)